Polar Capital Biotech R Inc

Performance History31/03/2024
Growth of 1,000 (EUR)
Polar Capital Biotech R Inc
Fund28.612.1-1.411.79.5
+/-Cat9.415.111.310.65.8
+/-Idx2.85.21.61.8-0.5
 
Key Stats
NAV
22/04/2024
 USD 41.23
Day Change 1.12%
Morningstar Category™ Sector Equity Biotechnology
ISIN IE00B3XLHR60
Fund Size (Mil)
22/04/2024
 USD 1626.61
Share Class Size (Mil)
22/04/2024
 USD 603.61
Max Initial Charge 5.00%
Ongoing Charge
31/12/2023
  1.62%
Investment Objective: Polar Capital Biotech R Inc
The investment objective of the Fund is to preserve capital and achieve long term capital appreciation.
Returns
Trailing Returns (EUR)22/04/2024
YTD1.08
3 Years Annualised5.29
5 Years Annualised13.55
10 Years Annualised15.74
12 Month Yield 0.00
Dividend Paying Frequency Annually
Management
Manager Name
Start Date
David Pinniger
31/10/2013
Gareth Powell
31/10/2013
Inception Date
31/10/2013
Advertisement
Benchmarks
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology NR USDMorningstar Gbl Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNot Specific
GrowthYes
IncomeNo
HedgingNo
OtherNot Specific
Portfolio Profile for  Polar Capital Biotech R Inc29/02/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stocks98.990.0098.99
Bonds0.020.000.02
Cash1.130.150.98
Other0.000.000.00
Top 5 Regions%
United States74.25
Europe - ex Euro10.25
Eurozone6.65
United Kingdom4.86
Canada4.00
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Regeneron Pharmaceuticals IncHealthcareHealthcare6.59
Zealand Pharma A/SHealthcareHealthcare5.48
Celldex Therapeutics IncHealthcareHealthcare4.78
argenx SEHealthcareHealthcare4.75
Blueprint Medicines CorpHealthcareHealthcare4.39
Polar Capital Biotech R Inc
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookie Settings        Disclosures